Vivos Therapeutics Acquires Stake in SOD Sciences, Eyes Chronic Disease Detection
Event summary
- Vivos Therapeutics to acquire 11% stake in SOD Sciences and 50% interest in pseudohypoxia test for $12M in Series C Preferred Stock.
- Transaction expected to close October 15, 2026, subject to customary conditions.
- Potential collaboration with Cleveland Clinic Weston and marketing relationship with AHA.
- Vivos aims to regain Nasdaq compliance through increased stockholders’ equity.
- Revenue sharing model: 80% contribution margin on Vivos products, 50/50 on joint test sales.
The big picture
Vivos Therapeutics is expanding its diagnostic capabilities beyond sleep apnea into chronic disease detection, a strategic shift that aligns with growing industry focus on early intervention. The $12M transaction, while dilutive, aims to bolster stockholders’ equity and regain Nasdaq compliance, setting the stage for potential profitability in early 2027. Success hinges on executing high-margin partnerships and validating the pseudohypoxia test’s clinical utility.
What we're watching
- Regulatory Compliance
- Whether Vivos can regain Nasdaq compliance through this transaction and subsequent capital raising.
- Revenue Potential
- The pace at which joint marketing agreements with Cleveland Clinic and AHA can drive new revenue streams.
- Clinical Validation
- How quickly the pseudohypoxia test can be clinically validated to support commercialization efforts.
Related topics
